A novel anticancer agent, retigeric acid B, displays proliferation inhibition, S phase arrest and apoptosis activation in human prostate cancer cells

Chemico-Biological Interactions

Volumn 188, Issue 3, 2010, Pages 598-606

  Liu, Han ^a   Liu, Yi Qing ^a   Liu, Yong Qing ^a   Xu, Ai Hui ^a   Young, Charles Y F ^b   Yuan, Hui Qing ^a   Lou, Hong Xiang ^a  

^a SHANDONG UNIVERSITY   (China)

^b DEPARTMENT OF UROLOGY   (United States)

Author keywords

Apoptosis; Cell cycle; LNCaP; PC 3; Retigeric acid B

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BROXURIDINE; CASPASE 3; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; RETIGERIC ACID B; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOWN REGULATION; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; S PHASE; TRANSCRIPTION, GENETIC; TRITERPENES;

EID: 78149470249     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.07.024     Document Type: Article

References (37)

1. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
2. So A., Gleave M., Hurtado-Col A., Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J. Urol. 2005, 23:1-9.
3. Castilla C., Congregado B., Chinchon D., Torrubia F.J., Japon M.A., Saez C. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 2006, 147:4960-4967.
4. Gleave M.E., Zellweger T., Chi K., Miyake H., Kiyama S., July L., Leung S. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest. New Drugs 2002, 20:145-158.
5. Krajewska M., Krajewski S., Banares S., Huang X., Turner B., Bubendorf L., Kallioniemi O.P., Shabaik A., Vitiello A., Peehl D., Gao G.J., Reed J.C. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin. Cancer Res. 2003, 9:4914-4925.
6. Li X., Marani M., Mannucci R., Kinsey B., Andriani F., Nicoletti I., Denner L., Marcelli M. Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res. 2001, 61:1699-1706.
7. Yamanaka K., Rocchi P., Miyake H., Fazli L., Vessella B., Zangemeister-Wittke U., Gleave M.E. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol. Cancer Ther. 2005, 4:1689-1698.
8. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., Korsmeyer S.J., Proapoptotic B.A.X. BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
9. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351:1502-1512.
10. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M., Benson M.C., Small E.J., Raghavan D., Crawford E.D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351:1513-1520.
11. Barnes S. Role of phytochemicals in prevention and treatment of prostate cancer. Epidemiol. Rev. 2001, 23:102-105.
12. Kucuk O. Chemoprevention of prostate cancer. Cancer Metastasis Rev. 2002, 21:111-124.
13. Singh R.P., Dhanalakshmi S., Agarwal R. Phytochemicals as cell cycle modulators - a less toxic approach in halting human cancers. Cell Cycle 2002, 1:156-161.
14. Liu J.J., Huang B., Hooi S.C. Acetyl-keto-beta-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells. Br. J. Pharmacol. 2006, 148:1099-1107.
15. Syrovets T., Gschwend J.E., Buchele B., Laumonnier Y., Zugmaier W., Genze F., Simmet T. Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J. Biol. Chem. 2005, 280:6170-6180.
16. Yuan H.Q., Kong F., Wang X.L., Young C.Y., Hu X.Y., Lou H.X. Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem. Pharmacol. 2008, 75:2112-2121.
17. Wang X.N., Zhang H.J., Ren D.M., Ji M., Yu W.T., Lou H.X. Lobarialides A-C, antifungal triterpenoids from the lichen Lobaria kurokawae. Chem. Biodivers. 2009, 6:746-753.
18. Sun L., Sun S., Cheng A., Wu X., Zhang Y., Lou H. In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans. Antimicrob. Agents Chemother. 2009, 53:1586-1591.
19. Howard C.M., Claudio P.P., De Luca A., Stiegler P., Jori F.P., Safdar N.M., Caputi M., Khalili K., Giordano A. Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop. Cancer Res. 2000, 60:2737-2744.
20. Lee K.Y., Myung K. PCNA modifications for regulation of post-replication repair pathways. Mol. Cell 2008, 26:5-11.
21. Honda T., Gjertsen B.T., Spurgers K.B., Briones F., Lee S.J., Hobbs M.L., Meyn R.E., Roth J.A., Logothetis C., McDonnell T.J. Restoration of bax in prostate cancer suppresses tumor growth and augments therapeutic cell death induction. Anticancer Res. 2001, 21:3141-3146.
22. Zegarra-Moro O.L., Schmidt L.J., Huang H., Tindall D.J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 2002, 62:1008-1013.
23. Eder I.E., Hoffmann J., Rogatsch H., Schafer G., Zopf D., Bartsch G., Klocker H. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther. 2002, 9:117-125.
24. McKeon F., Melino G. Fog of war: the emerging p53 family. Cell Cycle 2007, 6:229-232.
25. Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J. Cell. Biochem. 2004, 91:223-231.
26. Lee J.T., Lehmann B.D., Terrian D.M., Chappell W.H., Stivala F., Libra M., Martelli A.M., Steelman L.S., McCubrey J.A. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008, 7:1745-1762.
27. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem. Pharmacol. 2000, 60:1051-1059.
28. Kan S.F., Yu C.H., Pu H.F., Hsu J.M., Chen M.J., Wang P.S. Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. J. Cell. Biochem. 2007, 101:44-56.
29. Kai L., Samuel S.K., Levenson A.S. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int. J. Cancer 2010, 126:1538-1548.
30. Zhu Y., Alvarez C., Doll R., Kurata H., Schebye X.M., Parry D., Lees E. Intra-S-phase checkpoint activation by direct CDK2 inhibition. Mol. Cell. Biol. 2004, 24:6268-6277.
31. Ortega S., Prieto I., Odajima J., Martin A., Dubus P., Sotillo R., Barbero J.L., Malumbres M., Barbacid M. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 2003, 35:25-31.
32. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 2009, 9:153-166.
33. Golsteyn R.M. Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle. Cancer Lett. 2005, 217:129-138.
34. Gasparian A.V., Yao Y.J., Kowalczyk D., Lyakh L.A., Karseladze A., Slaga T.J., Budunova I.V. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J. Cell Sci. 2002, 115:141-151.
35. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2:301-310.
36. Karin M., Yamamoto Y., Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 2004, 3:17-26.
37. Takada Y., Ichikawa H., Badmaev V., Aggarwal B.B. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. J. Immunol. 2006, 176:3127-3140.